All In Biotech

Drug Trial Radar · NCT05173142

A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid Tumors

A Phase Ib/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

190

Actual

Start

Jan 22, 2022

Primary completion

Jul 17, 2025

Study completion Jan 17, 2026

Sponsor

Lead sponsor
Hutchison Medipharma LimitedIndustry
Sponsor type
Industry
First posted
Dec 29, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination with Chemotherapy or Toripalimab in Advanced Solid Tumors

Conditions

  • Solid Tumor

Interventions

  • HMPL-453Drug

    HMPL-453 administered orally.

  • gemcitabine and cisplatinDrug

    Gemcitabine and Cisplatin administered intravenously.

  • toripalimabDrug

    Toripalimab administered intravenously.

  • DocetaxelDrug

    Docetaxel administered intravenously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability(Incidence and severity of adverse events (AEs))Time frame: 6 months after the last patient enrolled
  2. Preliminary efficacy/Objective response rate (ORR)Time frame: up to 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chinese PLA General Hospital

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.